<DOC>
	<DOC>NCT01347528</DOC>
	<brief_summary>TELEMED-HF is a randomized, controlled clinical intervention trial designed to: (1) examine the efficacy of an electronic Medication Adherence Support System (MASS) in improving and monitoring patients' medication adherence; to (2) i determine the effect of medication adherence on hospitalization and health care consumption.</brief_summary>
	<brief_title>Improving MEDication Adherence in Chronic Heart Failure Using a TELEmedicine Device (TELEMED-HF)</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Stable systolic heart failure New York Heart Association functional class IIIII, with a decreased pump function (left ventricular ejection fraction (LVEF) &lt;45%) Titrated to the most optimal doses of ACEinhibitor or Angiotensin Receptor Blocker, and betablocker Receiving stable doses of at least 3 heart failure medications (at multiple times during the day) for 1 month with no plans to add or adjust heart failure medications or titrate further in the immediate future. Age younger than 50 years Diastolic heart failure (intact pump function) Myocardial infarction, invasive treatment (percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)), or hospitalization within 1 month prior to inclusion Lifethreatening comorbid conditions (e.g., cancer) Diminished mental capacities (suspected cognitive decline will be confirmed by a mini mental state examination (MMSE)) History of psychiatric disorders apart from affective disorders (depression and anxiety disorders)</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Medication adherence</keyword>
	<keyword>Heart failure</keyword>
	<keyword>Telemonitoring</keyword>
	<keyword>Determinants of adherence</keyword>
</DOC>